Deals·October 22, 2026 at 10:02 PM EDT·1 source
Gilead strikes $1.3B upfront China deal for oral IL-23 drug
acquisition, log scale$1.3B
$100M$1B$10B$100B
What happened
- Gilead will pay PepStar Therapeutics $1.28 billion upfront for a Phase 1 oral IL-23 drug asset.
- The transaction expands Gilead’s presence in China and the inflammation market.
Upfront payment
$1.28 billion
Development stage
Phase 1
Why it matters
The deal gives healthcare and life-sciences investors insight into the premium large biopharma companies are placing on early-stage inflammation assets and China expansion.
Deal terms
acquisition
Gilead → PepStar Therapeutics’ oral IL-23 drug asset
Value
$1.3B
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Who is involved
acquiringGilead strikes $1.3B upfront China deal for oral IL-23 drugPepStar Therapeutics’ oral IL-23 drug assettargetGileadbuyer
CompanyThe deal
Sources (1)
- Endpoints NewsOct 23Gilead strikes $1.3B upfront China deal for oral IL-23 drug
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.